U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome
The FDA accepted Teva's NDA for ecopipam and granted Priority Review for the treatment of pediatric Tourette syndrome, with a PDUFA action date set for late Q1 2027. Supported by positive Phase 3 data published in JAMA Neurology, ecopipam is a first-in-class D1 receptor antagonist that demonstrated a 53% decreased risk of relapse compared to placebo.
Key figures
- Drug Name
- Ecopipam (EBS-101)
- Phase Of Trial
- Phase 3
- Pdufa date
- late Q1 2027
- Phase3 p value
- 0.008
- Phase2b p value
- 0.01
- Priority review
- Yes
- Orphan designation
- Yes
- Relapse risk reduction
- 53%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.